This group promotes and supports research on early chemopreventive agent development, from preclinical studies to phase I clinical trials. The focus is to identify and develop agents with the potential to help detect, block, reverse, or delay early stages of cancer. Preclinical studies evaluate potential new drugs and combinations in model systems using emergent knowledge of genetic and biochemical mechanisms, while early phase trials emphasize pharmacokinetics, efficacy, and safety.
This is a listing of Requests for Proposals and Program Announcements specific to the group's key programs.
The group administers the PREVENT Cancer Preclinical Drug Development Program; a unique partnership to facilitate cancer preventative drug development.
This section contains a listing of journal articles, books and supplements.
Mission, staff list, and contact information are in this section.
Back to top
